Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults
- PMID: 40465828
- PMCID: PMC12404734
- DOI: 10.1093/brain/awaf211
Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults
Abstract
There has been a rapid growth in research on peripheral fluid biomarkers for Alzheimer's disease (AD) and AD-related dementias, because they are non-invasive, relatively inexpensive and easily accessible. The most commonly used plasma biomarkers include amyloid-β (Aβ), phosphorylated tau (p-tau), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP). The extent to which distinct profiles of multiple plasma biomarkers correlate with common neuropathologies is unclear. Using clinicopathologic data from 405 community-dwelling older adults, we applied latent profile analysis to four plasma biomarkers, i.e. Aβ42/40 ratio, p-tau217, NfL and GFAP, and examined the correlates of the latent profiles with four degeneration measures: AD, Lewy bodies, limbic-predominant age-related TDP-43 encephalopathy (LATE) and hippocampal sclerosis; and five vascular measures: chronic macroscopic infarcts, microinfarcts, cerebral amyloid angiopathy, atherosclerosis and arteriosclerosis. On average, participants died at the age of 89, and blood samples for plasma biomarkers were measured 3.9 years before death. Over 75% were female, and 24% were non-Latino Black. We observed three distinct biomarker profiles. Profile 1, characterized by low p-tau217, low GFAP, low NfL and high Aβ42/40, represented most participants (55.6%), with better than average biomarker levels. Both Profile 2 and Profile 3 showed worse than average biomarker levels. Profile 2, representing 34.8% of the participants, was high in p-tau217 and GFAP. In contrast, Profile 3, representing 9.6% of the participants, was high in NfL and GFAP. Examination of neuropathologic correlates of these plasma biomarker profiles revealed that Profile 2 exemplifies older adults with a high burden of neurodegeneration; almost all participants (92.9%) in Profile 2 had a diagnosis of pathologic AD, and the group also had the highest percentage of participants with Lewy bodies (41.1%). In comparison, Profile 3 exemplifies older adults with more severe vascular conditions; participants in this group had the highest percentage of macroscopic infarcts (31.6%) and moderate or severe atherosclerosis (42.1%). Together, these findings suggest that common plasma biomarkers may exhibit profiles reflective of distinct pathophysiologic processes.
Keywords: AD/ADRD; cerebrovascular conditions; latent profile analysis; neurodegeneration; plasma biomarkers.
© The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
J.L.D. is an inventor on patents or patent applications assigned to Eli Lilly and Company relating to the assays, methods, reagents and/or compositions of matter for P-tau assays and Aβ targeting therapeutics. JLD has/is served/serving as a consultant or on advisory boards for Eisai, Abbvie, Genotix Biotechnologies Inc, Gates Ventures, Gate Neurosciences, Dolby Family Ventures, Karuna Therapeutics, Alzheimer’s Disease Drug Discovery Foundation, AlzPath Inc., Cognito Therapeutics, Inc., Eli Lilly and Company, Prevail Therapeutics, Neurogen Biomarking, Spear Bio, Rush University, University of Kentucky, Tymora Analytical Operations, and Quanterix. JLD has received research support from ADx Neurosciences, Fujirebio, Roche Diagnostics and Eli Lilly and Company in the past two years. JLD has received speaker fees from Eli Lilly and Company and LabCorp. J.L.D. is a founder and advisor for Monument Biosciences and Dage Scientific LLC. J.L.D. has stock or stock options in Eli Lilly and Company, Genotix Biotechnologies, AlzPath Inc., Neurogen Biomarking, and Monument Biosciences. All other authors report no competing interests.
Comment in
-
Plasma biomarker profiles in ageing: decoding neurodegeneration in vivo.Brain. 2025 Sep 3;148(9):3032-3033. doi: 10.1093/brain/awaf281. Brain. 2025. PMID: 40795087 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous